HALO » Topics » Competition

These excerpts taken from the HALO 10-K filed Mar 13, 2009.
Competition
 
HYLENEX
 
Other manufacturers have FDA-approved products for use as spreading agents, including ISTA Pharmaceuticals, Inc., with an ovine (ram) hyaluronidase, Vitrase®, Amphastar Pharmaceuticals, Inc., with a bovine hyaluronidase, Amphadasetm, and Primapharm, Inc. also with a bovine hyaluronidase, Hydasetm. In addition, some commercial pharmacies compound hyaluronidase preparations for institutions and physicians even though compounded preparations are not FDA-approved products. Some compounding pharmacies do not test every batch of product for drug concentration, sterility and lack of pyrogens. In addition, HYLENEX is priced at a significant premium compared to the animal-derived hyaluronidases currently in the marketplace. This price premium may slow market adoption of HYLENEX and make market penetration difficult.
 
Cumulase
 
A key clinical selling point for Cumulase is that it may eliminate the risk of animal pathogen transmission and toxicity inherent in slaughterhouse preparations. The competing enzymes are of animal origin, creating an opportunity for a recombinant human enzyme alternative. Cumulase is priced at a premium compared to the animal-derived products sold by these leading IVF suppliers, which may make market penetration difficult.
 
Competition
 
HYLENEX
 
Other manufacturers have FDA-approved products for use as spreading agents, including ISTA Pharmaceuticals, Inc., with an ovine (ram) hyaluronidase, Vitrase®, Amphastar Pharmaceuticals, Inc., with a bovine hyaluronidase, Amphadasetm, and Primapharm, Inc. also with a bovine hyaluronidase, Hydasetm. In addition, some commercial pharmacies compound hyaluronidase preparations for institutions and physicians even though compounded preparations are not FDA-approved products. Some compounding pharmacies do not test every batch of product for drug concentration, sterility and lack of pyrogens. In addition, HYLENEX is priced at a significant premium compared to the animal-derived hyaluronidases currently in the marketplace. This price premium may slow market adoption of HYLENEX and make market penetration difficult.
 
Cumulase
 
A key clinical selling point for Cumulase is that it may eliminate the risk of animal pathogen transmission and toxicity inherent in slaughterhouse preparations. The competing enzymes are of animal origin, creating an opportunity for a recombinant human enzyme alternative. Cumulase is priced at a premium compared to the animal-derived products sold by these leading IVF suppliers, which may make market penetration difficult.
 
Competition


 




HYLENEX


 



Other manufacturers have FDA-approved products for use as
spreading agents, including ISTA Pharmaceuticals, Inc., with an
ovine (ram) hyaluronidase,
Vitrase®,

Amphastar Pharmaceuticals, Inc., with a bovine hyaluronidase,
Amphadasetm,

and Primapharm, Inc. also with a bovine hyaluronidase,
Hydasetm.

In addition, some commercial pharmacies compound hyaluronidase
preparations for institutions and physicians even though
compounded preparations are not FDA-approved products. Some
compounding pharmacies do not test every batch of product for
drug concentration, sterility and lack of pyrogens. In addition,
HYLENEX is priced at a significant premium compared to the
animal-derived hyaluronidases currently in the marketplace. This
price premium may slow market adoption of HYLENEX and make
market penetration difficult.


 




Cumulase


 



A key clinical selling point for Cumulase is that it may
eliminate the risk of animal pathogen transmission and toxicity
inherent in slaughterhouse preparations. The competing enzymes
are of animal origin, creating an opportunity for a recombinant
human enzyme alternative. Cumulase is priced at a premium
compared to the animal-derived products sold by these leading
IVF suppliers, which may make market penetration difficult.


 




Competition


 




HYLENEX


 



Other manufacturers have FDA-approved products for use as
spreading agents, including ISTA Pharmaceuticals, Inc., with an
ovine (ram) hyaluronidase,
Vitrase®,

Amphastar Pharmaceuticals, Inc., with a bovine hyaluronidase,
Amphadasetm,

and Primapharm, Inc. also with a bovine hyaluronidase,
Hydasetm.

In addition, some commercial pharmacies compound hyaluronidase
preparations for institutions and physicians even though
compounded preparations are not FDA-approved products. Some
compounding pharmacies do not test every batch of product for
drug concentration, sterility and lack of pyrogens. In addition,
HYLENEX is priced at a significant premium compared to the
animal-derived hyaluronidases currently in the marketplace. This
price premium may slow market adoption of HYLENEX and make
market penetration difficult.


 




Cumulase


 



A key clinical selling point for Cumulase is that it may
eliminate the risk of animal pathogen transmission and toxicity
inherent in slaughterhouse preparations. The competing enzymes
are of animal origin, creating an opportunity for a recombinant
human enzyme alternative. Cumulase is priced at a premium
compared to the animal-derived products sold by these leading
IVF suppliers, which may make market penetration difficult.


 




These excerpts taken from the HALO 10-K filed Mar 14, 2008.
Competition
 
Cumulase
 
A key clinical selling point for Cumulase is that it may eliminate the risk of animal pathogen transmission and toxicity inherent in slaughterhouse preparations. The competing enzymes are of animal origin, creating an opportunity for us to enter the market with a recombinant human enzyme alternative. The leading IVF suppliers are CooperSurgical, Irvine Scientific, and Cook Ob/Gyn (all three of these companies produce bovine products) in the US, and MediCult (ovine product) and Vitrolife (bovine product) outside the US. Cumulase is priced at a premium compared to the animal-derived products sold by these leading IVF suppliers, which may make market penetration difficult.
 
Hylenex
 
Other manufacturers have FDA approved products for use as spreading agents, including ISTA Pharmaceuticals, Inc. (“ISTA”), with an ovine (ram) hyaluronidase, Vitrase®, Amphastar Pharmaceuticals, Inc., with a bovine hyaluronidase, Amphadasetm, and Primapharm, Inc. also with a bovine hyaluronidase, Hydasetm. The FDA has determined that Amphadase, Hydase, Hylenex and Vitrase are distinct new chemical entities and hence afforded five years of market exclusivity. The five year market exclusivity precludes identical new chemical entity products from being marketed for a period of five years. As each of these products is established as distinctly different new chemical entities, the marketing exclusivity granted does not prohibit the marketing of the products. In addition, some commercial pharmacies now compound hyaluronidase preparations for institutions and physicians. However, there are some concerns with using a compounded sterile product. Compounded preparations are not FDA-approved products. Some compounding pharmacies do not test every batch of product for drug concentration, sterility, and lack of pyrogens. In addition, Hylenex is priced at a significant premium compared to the animal-derived hyaluronidases currently in the marketplace. This price premium may slow market adoption of Hylenex and make market penetration difficult.


6


Table of Contents

Competition


 




Cumulase


 



A key clinical selling point for Cumulase is that it may
eliminate the risk of animal pathogen transmission and toxicity
inherent in slaughterhouse preparations. The competing enzymes
are of animal origin, creating an opportunity for us to enter
the market with a recombinant human enzyme alternative. The
leading IVF suppliers are CooperSurgical, Irvine Scientific, and
Cook Ob/Gyn (all three of these companies produce bovine
products) in the US, and MediCult (ovine product) and Vitrolife
(bovine product) outside the US. Cumulase is priced at a premium
compared to the animal-derived products sold by these leading
IVF suppliers, which may make market penetration difficult.


 




Hylenex


 



Other manufacturers have FDA approved products for use as
spreading agents, including ISTA Pharmaceuticals, Inc.
(“ISTA”), with an ovine (ram) hyaluronidase,
Vitrase®,
Amphastar Pharmaceuticals, Inc., with a bovine hyaluronidase,
Amphadasetm,
and Primapharm, Inc. also with a bovine hyaluronidase,
Hydasetm.
The FDA has determined that Amphadase, Hydase, Hylenex and
Vitrase are distinct new chemical entities and hence afforded
five years of market exclusivity. The five year market
exclusivity precludes identical new chemical entity products
from being marketed for a period of five years. As each of these
products is established as distinctly different new chemical
entities, the marketing exclusivity granted does not prohibit
the marketing of the products. In addition, some commercial
pharmacies now compound hyaluronidase preparations for
institutions and physicians. However, there are some concerns
with using a compounded sterile product. Compounded preparations
are not FDA-approved products. Some compounding pharmacies do
not test every batch of product for drug concentration,
sterility, and lack of pyrogens. In addition, Hylenex is priced
at a significant premium compared to the animal-derived
hyaluronidases currently in the marketplace. This price premium
may slow market adoption of Hylenex and make market penetration
difficult.





6





Table of Contents







This excerpt taken from the HALO 10-K filed Mar 9, 2007.
Competition
 
Cumulase
 
A key clinical selling point for Cumulase is that it may eliminate the risk of animal pathogen transmission and toxicity inherent in slaughterhouse preparations. The competing enzymes are of animal origin, creating an opportunity for Halozyme to enter the market with a recombinant human enzyme alternative. The leading IVF suppliers are CooperSurgical, Irvine Scientific, and Cook Ob/Gyn (all three of these companies produce bovine products) in the US, and MediCult (ovine product) and Vitrolife (bovine product) outside the US. Cumulase is priced at a premium to the animal-derived products sold by these leading IVF suppliers, which may make market penetration difficult.
 
Hylenex
 
Other manufacturers have FDA approved products for use as spreading agents, including ISTA Pharmaceuticals, Inc. (“ISTA”), with an ovine (ram) hyaluronidase, Vitrase®, Amphastar Pharmaceuticals, Inc., with a bovine (bull) hyaluronidase, Amphadasetm, and Primapharm, Inc. also with a bovine hyaluronidase, Hydasetm. The FDA has determined that Amphadase, Hydase, Hylenex and Vitrase are distinct new chemical entities and hence afforded five years of market exclusivity. The five year market exclusivity precludes identical new chemical entity products from being marketed for a period of five years. As each of these products are established as distinctly different new chemical entities the marketing exclusivity granted does not prohibit the marketing of the products. In addition, some commercial pharmacies now compound hyaluronidase preparations for institutions and physicians. However, there are some concerns with using a compounded sterile product. Compounded preparations are not FDA-approved products. Some compounding pharmacies do not test every batch of product for drug concentration, sterility, and lack of pyrogens. In addition, we anticipate that Hylenex will be priced at a significant premium to the animal-derived hyaluronidases currently in the marketplace. This anticipated price premium may slow market adoption of Hylenex and make market penetration difficult.
 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki